Go Pro

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:HSTO

Histogen (HSTO) Stock Price, News & Analysis

Histogen logo

About Histogen Stock (NASDAQ:HSTO)

Key Stats

Today's Range
$0.0003
$0.0013
50-Day Range
N/A
52-Week Range
$0.05
$0.55
Volume
1,625 shs
Average Volume
10,369 shs
Market Capitalization
$5.34 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Histogen, Inc. is a clinical‐stage biotechnology company headquartered in San Diego, California, that specializes in the development of regenerative medicine products for hair restoration and skin rejuvenation. The company’s proprietary technology harnesses the secreted growth factors, cytokines and extracellular matrix components produced by “embryonic‐like” human cells cultured under low‐oxygen conditions. By concentrating these biologically active molecules into a conditioned medium, Histogen aims to create off‐the‐shelf therapeutics that stimulate tissue repair and regeneration.

Histogen’s lead product candidates include HST‐001, a formulation under investigation for accelerating wound healing and improving skin quality, and HST‐002, a topical treatment designed to promote hair follicle health and counteract androgenetic alopecia. Both programs have advanced through initial clinical evaluations, demonstrating favorable safety profiles and signs of biological activity. The company holds a portfolio of patents protecting its cell‐culture processes and methods of use in dermatological and aesthetic indications.

Founded in 2007, Histogen operates research and GMP manufacturing facilities in the United States and collaborates with external laboratories and academic partners to expand its pipeline. Led by founder and Chief Executive Officer Christopher J. Bradley, the company continues to pursue late‐stage clinical development and strategic partnerships aimed at commercializing its regenerative therapeutics worldwide.

AI Generated. May Contain Errors.

Receive HSTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Histogen and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HSTO Stock News Headlines

Barricks gold output fell from 2 million ounces to 719000
Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-largest miner running on fumes. Newmont's $15 billion purchase of Newcrest, the largest mining deal in history, still couldn't keep output growing, proof that majors must keep buying to survive. With record cash flows and shrinking mines, gold majors are positioned to launch a wave of acquisitions targeting the best junior assets.tc pixel
Histogen Files For Voluntary Chapter 11 Bankruptcy Protection
See More Headlines

HSTO Stock Analysis - Frequently Asked Questions

Histogen Inc. (NASDAQ:HSTO) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($1.80) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.20) by $0.40. The firm had revenue of $0.59 million for the quarter.

Shares of Histogen reverse split on Friday, June 3rd 2022.The 1-20 reverse split was announced on Friday, June 3rd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 3rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Histogen investors own include Tesla (TSLA), Bionano Genomics (BNGO), HubSpot (HUBS), Meta Platforms (META) and TherapeuticsMD (TXMD).

Company Calendar

Last Earnings
11/10/2021
Today
8/14/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:HSTO
CIK
1383701
Fax
N/A
Employees
20
Year Founded
2007

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$19 thousand
Price / Sales
0.28
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.13 per share
Price / Book
0.00

Miscellaneous

Outstanding Shares
4,270,000
Free Float
N/A
Market Cap
$5.34 thousand
Optionable
Not Optionable
Beta
1.19

Social Links

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (NASDAQ:HSTO) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners